Last reviewed · How we verify
Synribo (OMACETAXINE MEPESUCCINATE)
At a glance
| Generic name | OMACETAXINE MEPESUCCINATE |
|---|---|
| Sponsor | Teva Pharms Intl |
| Drug class | omacetaxine mepesuccinate |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2012 |
Approved indications
- Chronic myeloid leukemia
Common side effects
Key clinical trials
- New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (PHASE2)
- Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML) (PHASE1)
- VAH vs VA in Newly Diagnosed Elderly AML (PHASE3)
- Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. (PHASE2)
- Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML (PHASE2)
- Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia
- Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML (PHASE2)
- Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Synribo CI brief — competitive landscape report
- Synribo updates RSS · CI watch RSS
- Teva Pharms Intl portfolio CI